Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
2
Multiple of current chicken housing capacityWording
Conditional
How definitive the wording is.Announced details
Chicken egg bioreactor businessBrazzein
Applicable field (uses covered by this announcement)
Research reagentsPharmaceuticals, cosmetics and food ingredientsIndustrial applicationsProcessed foods and beverages
Launch dateAround winter 2026 (scheduled; facility operations begin)
Location (as indicated in this announcement)
Otaru, Hokkaido
Chicken housing capacity is expected to be double the current level
Impact on Business Performance
The impact on the performance of the Group as a whole for the current fiscal year is expected to be minor
The company does not address Contract Value / Offering price.
Source (materials cited by the company)
“Successfully Developed and Produced the Sweet Protein ‘Brazzein’ Using a Chicken Egg Bioreactor,” dated 13 November 2025
| Item | Details |
|---|---|
| Names of Products / Services Covered | Chicken egg bioreactor business, Brazzein |
| Launch date | Around winter 2026 (scheduled; facility operations begin) |
| Applicable area | Research reagents, Pharmaceuticals, cosmetics and food ingredients, Industrial applications, Processed foods and beverages |
| Location | Otaru, Hokkaido |
| Location scale | Chicken housing capacity is expected to be double the current level |
| Impact on Business Performance | The impact on the performance of the Group as a whole for the current fiscal year is expected to be minor |
| Source | “Successfully Developed and Produced the Sweet Protein ‘Brazzein’ Using a Chicken Egg Bioreactor,” dated 13 November 2025 |
Items this document does not state (11)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateQuantitative EffectsUsage history
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To accelerate product development and practical implementation, advance the plan to create 50 types of genome-edited chickens by 2028, maintain and manage brazzein-expressing chickens, and advance the establishment of large-scale purification methods and evaluations, including safety assessments.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.